NEW YORK: After years of study costing $600 mln, the drugmaker says it won't break itself up. Boss Ian Read always seemed keener on acquisitions.

It's true the process helped close a conglomerate discount.

But Pfizer's sprawl and tendency to overpay means the gap may soon reappear.

Copyright Reuters, 2016